What is the purpose of this trial?
A Phase II Evaluation of Pembrolizumab, a Humanized Antibody Against PD-1, in the Treatment of Persistent or Recurrent Hypermutated/Ultramutated Endometrial Cancer Identified by Next Generation Sequencing (NGS) and Comprehensive Genomic Profiling (CGP)
Start Date: 09/23/2016
End Date: 12/31/2020
Last Updated: 09/12/2018
Study HIC#: 1605017712